Polymer-drug conjugates: Progress in polymeric prodrugs

Progress in Polymer Science (Oxford)

Volumn 31, Issue 4, 2006, Pages 359-397

  Khandare, Jayant ^a   Minko, Tamara ^a,b,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Conjugation; Drug delivery; Enhanced permeability and retention; In vivo and in vitro; Polymer; Prodrug

Indexed keywords

DRUG PRODUCTS; POLYETHYLENE GLYCOLS; PROTEINS; TOXICITY; TUMORS;

CONJUGATION; DRUG DELIVERY; ENHANCED PERMEABILITY AND RETENTION; IN VIVO AND IN VITRO; PRODRUG;

ORGANIC POLYMERS;

EID: 33646255225     PISSN: 00796700     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.progpolymsci.2005.09.004     Document Type: Review

References (118)

1. Lewis D.H. Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M., and Langer R. (Eds). Biodegradable polymers as drug delivery systems (1990), Marcel Dekker, New York 1-2
2. Kono K., Liu M., and Frechet J.M. Design of dendritic macromolecules containing folate or methotrexate residues. Bioconjugate Chem 10 6 (1999) 1115-1121
3. Thomas A.C., and Campbell J.H. Conjugation of an antibody to cross-linked fibrin for targeted delivery of anti-restenotic drugs. J Control Release 100 (2004) 357-377
4. Charrois G.J.R., and Allen T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta Biomembr 1663 (2004) 167-177
5. Maeda H., Seymour L.W., and Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem 5 (1992) 351-362
6. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2 (2003) 347-360
7. Satchi-Fainaro R., Wrasidlo W., Lode H.N., and Shabat D. Synthesis and characterization of a catalytic antibody-HPMA copolymer-conjugate as a tool for tumor selective prodrug activation. Bioorg Med Chem 10 (2002) 3023-3029
8. Kopecek J. Synthesis of tailor-made soluble polymeric drug carriers. In: Anderson J.M., and Kim S.W. (Eds). Recent advances in drug delivery systems (1984), Plenum Press, New York, NY 41-62
9. Duncan R. Sustained and controlled drug delivery systems. In: Robinson J.R., and Lee V. (Eds). Controlled drug delivery: fundamentals and applications (1987), Marcel Dekker, New York, NY 581-621
10. Hoste K., Winne K.D., and Schacht E. Polymeric prodrugs. Int J Pharm 277 (2004) 119-131
11. Oliyai R., and Stella V.J. Prodrugs of peptides and proteins for improved formulation and delivery. Annu Rev Pharmacol Toxicol 32 (1993) 521-544
12. David A., Kopeckova P., Minko T., Rubinstein A., and Kopecek J. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. Eur J Cancer 40 (2004) 148-157
13. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2 (2002) 750-763
14. Jatzkewitz H. Peptamin (glycyl-l-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline). Z Naturforsch 10b (1955) 27-31
15. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Symp 51 (1975) 135-153
16. Sezaki H., Takakura Y., and Hashida M. Soluble macromolecular carriers for the delivery of antitumour drugs. Adv Drug Deliv Rev 3 (1989) 247-256
17. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
18. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2 (2003) 214-221
19. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22 (2001) 405-417
20. Hermanson G. Bioconjugate techniques (1996), Academic Press/Elsevier, San Diego, CA/Amsterdam
21. Cruz L.J., Iglesias E., Aguilar J.C., Quintana D., Garay H.E., Duarte C., et al. Study of different coupling agents in the conjugation of a V3-based synthetic MAP to carrier proteins. J Pept Sci 7 9 (2001) 511-518
22. Natarajan A., Xiong C.-Y., Albrecht H., DeNardo G.L., and DeNardo S.J. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjugate Chem 16 1 (2005) 113-121
23. Vaidya A.A., Lele B.S., Kulkarni M.G., and Mashelkar R.A. Enhancing ligand-protein binding in affinity thermoprecipitation: elucidation of spacer effects. Biotechnol Bioeng 64 (1999) 418-425
24. Khandare JJ, Kulkarni M G. Polymerizable macromers and preparation thereof. US patent (Council of Scientific and Industrial Research, New Delhi, IN 6,822,064.)2004.
25. Esswein A., Hanseler E., Montejano Y., Vitols K.S., and Huennekens F.M. Construction and therapeutic potential of a carboxypeptidase A/monoclonal antibody conjugate. Adv Enzyme Regul 31 (1991) 3-12
26. Melton R.G., Boyle J.M.B., Rogers G.T., Burke P., Bagshawe K.D., and Sherwood R.F. Optimization of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase-G. J Immunol Methods 158 (1993) 49-56
27. Searle F., Bier C., Buckley R.G., Newman S., Pedley R.B., Bagshawe K.D., et al. The potential of carboxypeptidase G,-antibody conjugates as anti-tumor agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G 2 and cytotoxicity of the conjugate against JAR choriocar-cinema cells in vitro. Br J Cancer 53 (1986) 377-384
28. Ulbrich K., and Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev 56 (2004) 1023-1050
29. Melton R.G. Preparation and purification of antibody-enzyme conjugates for therapeutic applications. Adv Drug Deliv Rev 22 (1996) 289-301
30. Hermanson G. Bioconjugate techniques (1996), Academic Press/Elsevier, San Diego p. 169-86
31. Sund M., Xu L.L., Rahman A., Qian B.F., Hammarstrom M.L., and Danielsson A. Reduced susceptibility to dextran sulphate sodium-induced colitis in the interleukin-2 heterozygous (IL-2) mouse. Immunology 14 (2005) 54-64
32. Takakura Y., and Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm Res 13 (1996) 820-831
33. McLeod A.D., Friend D.R., and Tozer T.N. Synthesis and chemical stability of glucocorticoid-dextran esters: potential prodrugs for colon-specific delivery. Int J Pharm 92 (1993) 105-114
34. Mehvar R., Dann R.O., and Hoganson D.A. Kinetics of hydrolysis of dextran-methylprednisolone succinate, a macromolecular prodrug of methylprednisolone, in rat blood and liver lysosomes. J Control Release 68 (2000) 53-61
35. Mehvar R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J Control Release 69 (2000) 1-25
36. Arefjev D.V., Domnina N.S., Komarova E.A., and Bilibin A.Y. Sterically hindered phenol-dextran conjugates: synthesis and radical scavenging activity. Eur Polym J 35 (1999) 279-284
37. Yura H., Yoshimura N., Hamashima T., Akamatsu K., Nishikawa M., Takakura Y., et al. Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. J Control Release 57 (1999) 87-99
38. Harada M., Murata J., Sakamura Y., Sakakibara H., Okuno S., and Suzuki T. Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats. J Control Release 71 (2001) 71-86
39. Munechika K., Sogame Y., Kishi N., Kawabata Y., Ueda Y., Yamanouchi K., et al. Tissue distribution of macromolecular conjugate, adriamycin linked to oxidized dextran, in rat and mouse bearing tumor-cells. Biol Pharm Bull 17 (1994) 1193-1198
40. Vercauteren R., Schacht E., and Duncan R. Effect of the chemical modification of dextran on the degradation by rat-liver lysosomal-enzymes. J Bioact Compat Polym 7 (1992) 346-357
41. Chau Y., Tan F.E., and Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase. IX. Bioconjugate Chem 15 (2004) 931-941
42. Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drug Deliv Rev 16 (1995) 157-182
43. Greenwald R.B., Choe Y.H., McGuire J., and Conover C.D. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 55 (2003) 217-250
44. Greenwald R.B., Gilbert C.W., Pendri A., Conover C.D., Xia J., and Martinez A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem 39 (1996) 424-431
45. Choe Y.H., Conover C.D., Wu D., Royzen M., and Greenwald R.B. Anticancer drug delivery systems: N4-acyl poly(ethyleneglycol) prodrugs of ara-C. I. Efficacy in solid tumors. J Control Release 79 (2002) 41-53
46. Choe Y.H., Conover C.D., Wu D., Royzen M., and Greenwald R.B. Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. J Control Release 79 (2002) 55-70
47. Schiavon O., Pasut G., Moro S., Orsolini P., Guiotto A., and Veronese F.M. PEG-Ara-C conjugates for controlled release. Eur J Med Chem 39 (2004) 123-133
48. Pechar M, Ulbrich K, Jelínková M, Ríhová B. Enzymatically degradable PEG multiblock copolymers with hydrazone-attached doxorubicin in cancer therapy. In: Sixth European symposium on controlled drug delivery, Noordwijkaan Zee (Neederlands); 2000. p. 155-6.
49. Ríhová B., Etrych T., Pechar M., Jelínková MM., Stastný M., Hovorka O., et al. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes. J Control Release 74 (2001) 225-232
50. Ulbrich K., Etrych T., Chytil P., Pechar M., Jelínková M., and Ríhová B. Polymeric anticancer drugs with pH-controlled activation. Int J Pharm 277 (2004) 63-72
51. Ulbrich K, Etrych T, Chytil P, Jelínková M, Ríhová B. Novel generation of polymer-drug-carrier systems for site-specific therapy. In: Seventh European symposium on controlled drug delivery systems, Noordwijkaan Zee, Netherlands; 2002. p. 3-15.
52. Abuchowski A., Es T.V., Palczuk N.C., and Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252 (1977) 578-3581
53. Yokoyama M., Miyauchi M., Yamada N., Okano T., Sakurai Y., Kataoka K., et al. Characterization and anticancer activity of the micelle forming polymeric anti-cancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res 50 (1990) 1693-1700
54. Ulbrich K., Subr V., Strohalm J., Plocová D., Jelínková M., and Ríhová B. Polymeric drugs based on conjugates of synthetic and natural macromolecules: I. Synthesis and physico-chemical characterisation. J Control Release 64 (2004) 63-79
55. Ríhová B., Jelínková M., Strohalm J., Subr V., Plocová D., Hovorka O., et al. Polymeric drugs based on conjugates of synthetic and natural macromolecules: II. Anti-cancer activity of antibody or (Fab') 2-targeted conjugates and combined therapy with immunomodulators. J Control Release 64 (2000) 241-261
56. Garnett M.C. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev 53 (2001) 171-216
57. Hashida M., Takakura Y., Matsumoto S., Sasaki H., Kato H., Kojima T., et al. Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity. Chem Pharm Bull 31 (1983) 2055-2063
58. Duncan R., and Spreafico F. Polymer conjugates-pharmacokinetic considerations for design and development. Clin Phamacokinet 27 (1994) 290-306
59. Hoste K., Schacht E.H., and Seymour L.W. New derivatives of polyglutamic acid as drug carrier systems. J Control Release 64 (2000) 53-61
60. Ulbrich K., and Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev 56 (2004) 1023-1050
61. Lee S., Greenwald R.B., McGuire J., Yang K., and Shi C. Drug delivery systems employing 1,6-elimination: releasable poly(ethylene glycol) conjugates of proteins. Bioconjugate Chem 12 (2001) 163-169
62. Lee L.S., Conover C.D., Shi C., Whitlow M., and Filpula D. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries of conjugation chemistries and compounds. Bioconjugate Chem 10 (1999) 973-981
63. Somack R., Saifek M.G.P., and Williams L.D. Preparation of long acting superoxide dismutase using high molecular weight polyethylene glycol (41,000-72,000 Daltons). Free Radic Res Commun 12 (1991) 553-562
64. Conover C.D., Pendri A., Lee C., Gilbert C.W., Shum K.L., and Greenwald R.B. Camptothecin deliverys: the antitumor activity of a camptothecin-polyethylene glycol ester transport form. Anticancer Res 17 (1997) 3361-3368
65. Minko T., Paranjpe P.V., Qiu B., Lalloo A., Won R., Stein S., et al. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 50 (2002) 143-150
66. Davis S., Abuchowski A., Park Y.K., and Davis F.F. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol 46 (1981) 649-652
67. Gunaseelan S., Debrah O., Li W., Leibowitz M.J., Rabson A.B., Stein S., et al. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay. Bioconjugate Chem 15 (2004) 1322-1333
68. Shenoy D.B., and Amiji M.M. Poly(ethylene oxide)-modified poly(ε-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 293 (2005) 261-720
69. Dharap S.S., Qiu B., Williams G.C., Sinko P., Stein S., and Minko T. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release 91 (2003) 61-73
70. Greenwald R.B. PEG drugs: an overview. J Control Release 74 (2001) 159-171
71. Bourke S.L., and Kohn J. Polymers derived from the amino acid l-tyrosine: polycarbonates, polyarylates and copolymers with poly(ethylene glycol). Adv Drug Deliv Rev 55 (2003) 447-466
72. Katchalski E. Poly(amino acids): achievements and prospects. In: Blout E.R., Bovey F.A., Goodman M., and Lotan N. (Eds). Peptides, polypeptides, and proteins-proceedings of the Rehovot symposium on poly(amino acids), polypeptides, and proteins and their biological implications (1974), Wiley, New York 1-13
73. Lotan N., Berger A., and Katchalski E. Conformation and conformational transitions of poly-α-amino acids in solution. In: Snell E.E., Boyer P.D., Meister A., and Sinsheimer R.L. (Eds). Annual review of biochemistry vol. 41 (1971), Annual Reviews, Inc., Palo Alto 869-901
74. Fasman G.D. The road from poly(α-amino acids) to the prediction of protein conformation. Biopolymers 26 (1987) S59-S79
75. Marre A.D., Soyez H., Schacht E., Shoaibi M.A., Seymour L.W., and Rihova B. Synthesis and evaluation of macromolecular prodrugs of mitomycin C. J Control Release 36 (1995) 87-97
76. Toncheva V., Wolfert M.A., Dash P.R., Oupicky D., Ulbrich K., Seymour L.W., et al. Novel vectors for gene delivery formed by self-assembly of DNA with poly(l-lysine) grafted with hydrophilic polymers. Biochim Biophys Acta 1380 (1998) 354-368
77. Crystal G. Transfer of genes to humans: early lessons and obstacles to success. Science 270 (1995) 404-410
78. Verma L.M., and Somia N. Gene therapy-promises, problems and prospects. Nature 389 (1997) 239-242
79. Luo D., and Saltzman W.M. Synthetic DNA delivery systems. Nat Biotechnol 18 (2000) 33-37
80. Smedt S.E.D., Demeester J., and Hennink W.E. Cationic polymer gene delivery systems. Pharm Res 17 (2000) 113-126
81. Putnam D., Gentry C.A., Pack D.W., and Langer R. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci USA 98 (2001) 1200-1205
82. Kopecek J., and Bazilova H. Poly(N-(hydroxypropyl)-methacrylamide). 1. Radical polymerization and copolymerization. Eur Polym J 9 (1973) 7-14
83. Duncan R., Cable R., Lloyd H.C., Rejmanova P., and Kopecek J. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci Rep 2 12 (1982) 1041-1046
84. Ulbrich K., Etrych T., Chytil P., Jelínková M., and Ríhová B. HPMA copolymers with pH-controlled release of doxorubicin. In vitro cytotoxicity and in vivo antitumor activity. J Control Release 87 (2003) 33-47
85. Hovorka O., Stastný M., Etrych T., Subr V., Strohalm J., Ulbrich K., et al. Differences in the intracellular fate of free and polymer-bound doxorubicin. J Control Release 80 (2002) 101-117
86. Deutsch H.M., Glinski J.A., Hermandez M., Haugwitz R.D., Narayanan L.V., Suffness M., et al. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent anti-tumor activity. J Med Chem 32 (1989) 788-792
87. Zhao Z., and Kingston D.G. Preparation of water-soluble prodrugs of taxol. J Nat Prod 54 (1991) 1607-1611
88. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P.A., Wedge S., Hume I.C., et al. Preclinical evaluation of polymer-bound doxorubicin. J Control Release 19 (1992) 331-346
89. Etrych T., Chytil P., Jelínková M., Ríhová B., and Ulbrich K. Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity. Macromol Biosci 2 (2002) 43-52
90. Etrych T., Jelínková M., Ríhová B., and Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J Control Release 73 (2001) 89-102
91. Ríhová B., Etrych T., Pechar M., Jelínková M., St'astný M., Hovorka O., et al. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes. J Control Release 74 (2001) 225-232
92. Minko T., Kopeckova P., Pozharov V., and Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 54 (1998) 223-233
93. Minko T., Kopeckova P., and Kopecek J. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multi-drug resistance in a human ovarian carcinoma cell line. J Control Release 59 (1999) 133-148
94. Kopecek J., Kopeckova P., Minko T., and Lu Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 50 (2000) 61-81
95. Kunath K., Kopeckova P., Minko T., and Kopecek J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line. Eur J Pharm Biopharm 49 (2000) 11-15
96. Minko T., Kopeckova P., and Kopecek J. Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J Control Release 71 (2001) 227-237
97. Tomalia D.A., and Fréchet J.M. Introduction to dendrimers and dendritic polymers. Prog Polym Sci 30 (2005) 294-324
98. Grainger D.W., and Okano T. Biomedical micro- and nanotechnology. Adv Drug Deliv Rev 55 (2003) 311-313
99. Newcome G.R., Moorefield C.N., Keith J.N., Baker G.R., and Escamilla G.H. Chemistry within a unimolecular micelle precursor: Boron superclusters by site- and depth-specific transformations of dendrimers. Angew Chem Int Ed 33 (1994) 2413-2420
100. Malik N., Wiwattanapatapee R., Klopsch R., Lorenz K., Frey H., Weener J.W., et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of I-l polyamidoamine dendrimers in vivo. J Control Release 65 (2002) 133-148
101. Kannan S., Kolhe P., Raykova V., Glibatec M., Kannan R.M., Lieh-Lai M., et al. Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. J Biomater Sci Polym Ed 15 (2004) 311-330
102. Quintana E., Raczka L., Piehler I., Lee A., Myc I., Majoros A.K., et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19 (2002) 1310-1316
103. Jevprasesphant R., Penny J., Attwood D., McKeown N.B., and Emanuele A.D. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm Res 20 (2003) 1543-1550
104. Tajarobi F., El-Sayed M., Rege B.D., Polli J.E., and Ghandehari H. Transport of polyamidoamine dendrimers across madin-d canine kidney cells. Int J Pharm 215 (2001) 263-267
105. Wiwattanapatapee R., Lomlim L., and Saramunee K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J Control Release 88 (2003) 1-9
106. Kolhe P., Khandare J., Pillai O., Kannan R.M., Kannan S., and Lieh-Lai M. Hyperbranched polymer drug conjugates with high drug payload for enhanced drug delivery. Pharm Res 21 (2004) 2185-2195
107. Khandare J., Kolhe P., Pillai O., Kannan S., Lieh-Lai M., and Kannan R.M. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconjugate Chem 16 (2005) 330-337
108. Rosowsky A., Forsch R., Uren J., and Wick M. Methotrexate analogues. Synthesis of new gamma substituted derivatives as dihydrofolate-reductase inhibitors and potential anticancer agents. J Med Chem 24 (1981) 1450-1455
109. Chau Y., Tan F.E., and Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjugate Chem 15 (2004) 931-941
110. Ragupathi G., Koganty R.R., Qiu D., Lloyd K.O., and Livingston P.O. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconjugate J 15 (1998) 217-221
111. Li C. Poly(l-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev 54 (2002) 695-713
112. Soyez H., Schacht E., and Vanderkerken S. The crucial role of spacer groups in macromolecular prodrug design. Adv Drug Deliv Rev 21 (1996) 81-106
113. Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 56 (2004) 491-509
114. Dharap S.S., Wang Y., Chandna P., Khandare J.J., Qiu B., Gunaseelan S., et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA 102 (2005) 12962-12967
115. Fang J., Sawa T., and Maeda H. Factors and mechanism of 'EPR' effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 519 (2003) 29-49
116. Greish K., Fang J., Inutsuka T., Nagamitsu A., and Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 42 (2003) 1089-1105
117. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41 (2001) 189-207
118. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agents. Cancer Res 46 (1986) 6387-6392